GUANGZHOU, China, Dec 2 (Bernama-BUSINESS WIRE) — LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
- December 2, 2021
0
715
Less than a minute
You can share this post!
administrator
Related Articles
KLCCP Stapled Group Appoints New CEO
- October 28, 2024
Promising Path To Sustainable Development: APO Launches Green…
- October 28, 2024